Sample size estimation
NSCLC, III-N2
NSCLC
The primary endpoint of this research was ORR, which was taken to calculate the sample size. Previous studies reported that the ORR of neoadjuvant Erlotinib for NSCLC (EMERGING-CTONG 1103) at stage III-N2 was 54.1%